文章核心观点 - 公司在第二季度取得了重要进展,包括继续推进临床项目,并计划在2024年底启动RLY-2608与Pfizer新型CDK4抑制剂阿替莫西克利的三联疗法临床试验[5] - 公司还披露了三个新的临床前项目,包括血管畸形、法布里病和NRAS靶向项目,这将有助于公司的持续增长和多元化[5][9][10] 关于RLY-2608 - RLY-2608双联疗法:继续在PI3Kα突变、HR+、HER2-局部晚期或转移性乳腺癌患者中进行400mg BID和600mg BID剂量扩展队列的入组,预计2024年第四季度将有更新数据[7] - RLY-2608三联疗法:继续在PI3Kα突变、HR+、HER2-局部晚期或转移性乳腺癌患者中进行RLY-2608+芙维司特兰+利博西克利三联疗法的入组,并宣布与辉瑞合作评估RLY-2608+阿替莫西克利+芙维司特兰三联疗法,计划于2024年底启动[7] - RLY-2608单药:继续在有PI3Kα突变的不可切除或转移性实体瘤患者中进行剂量递增部分的入组,并报告了多种肿瘤类型中的部分缓解反应[7] 关于其他项目 - 公司终止了与Genentech合作开发migoprotafib的协议,不会继续开发该项目[7] - 公司计划在2025年第一季度启动RLY-2608在血管畸形适应症的临床开发,2025年下半年启动法布里病和NRAS靶向项目的临床开发[11] 财务情况 - 截至2024年6月30日,公司拥有6.884亿美元的现金、现金等价物和投资,预计可为公司运营提供资金支持到2026年下半年[12] - 2024年第二季度研发费用为9,200万美元,较2023年同期增加,主要是由于RLY-2608ReDiscover试验的额外外部成本[13] - 2024年第二季度管理费用为2,010万美元,与2023年同期持平[14] - 2024年第二季度净亏损为9,221万美元,每股亏损0.69美元,较2023年同期有所改善[15]

CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 6, 2024. About Relay Therapeutics Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision medicine company transforming the d ...

3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 a.m. ET CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading- ...

CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen 5th Annual Oncology Innovation Summit, taking place virtually on Tuesday, May 28, 2024 at 9:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, Jun ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3923475 (State or other jurisdi ...

Exhibit 99.1 Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 Cambridge, Mass. – May 2, 2024 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-3923475 (State or other jurisdicti ...

Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3923475 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3923475 (State or other jurisdic ...